Current Pharmaco-therapeutic Approach on COVID-19 Admitted Patients in a Corona-dedicated Hospital in Khulna
Abstract
Background: The COVID-19 pandemic has been demanding possible pharmaco-therapeutic options to reduce the mortality associated with the disease by trying out the clinical efficacy of various therapeutic agents. Objective: Our purpose of the study was to explore the current pharmaco-therapeutic approaches to COVID-19 patients in different clinical categories. Methods: This is a descriptive observational study where 300 clinically diagnosed COVID-19-positive patients were included following inclusion & exclusion criteria at the study center. Patients’ demographic profiles and treatment plans were obtained using a specially designed form. The data were collated and analyzed using a Microsoft Excel spreadsheet and results were expressed in percentages. Results: Remdesivir, moxifloxacin, dexamethasone, meropenem, enoxaparin and other supportive drugs with different percentages in mild, moderate, severe & critical cases were frequently prescribed. Besides non-invasive oxygen therapy has been given in almost all patients. Conclusion: Antiviral, LMWH, broad-spectrum antibiotics, corticosteroids and other symptomatic drugs are the major treatment options for different clinical categories of COVID-19 patients. Mediscope 2024;11(1): 13-21
Read the paper
Related studies
- Structural and topological analysis of thiosemicarbazone-based metal complexes: computational and experimental study of bacterial biofilm inhibition and antioxidant activity
- Toward better cures for Mycobacterium abscessus lung disease
- Challenges for global antibiotic regimen planning and establishing antimicrobial resistance targets: implications for the WHO Essential Medicines List and AWaRe antibiotic book dosing
- Design, Synthesis and In vitro Antitubercular Effect of New Chalcone Derivatives Coupled with 1,2,3‐Triazoles: A Computational Docking Techniques
- Upregulation of pmrA, pmrB, pmrC, phoQ, phoP, and arnT genes contributing to resistance to colistin in superbug Klebsiella pneumoniae isolates from human clinical samples in Tehran, Iran
- Whole-genome sequencing of clinical isolates of Citrobacter Europaeus in China carrying blaOXA−48 and blaNDM−1
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.